10-Q: Protalix BioTherapeutics Reports Second Quarter 2024 Financial Results

Protalix BioTherapeutics reports a net loss for the second quarter of 2024, with a decrease in revenue from license and R&D services, but an increase in sales to Brazil and Pfizer.

Summary

• Protalix BioTherapeutics reported a net loss of $2.2 million for the three months ended June 30, 2024, and a net loss of $6.8 million for the six months ended June 30, 2024.
• Revenue from selling goods decreased by 12% in the second quarter of 2024 compared to the same period in 2023, primarily due to a decrease in sales to Chiesi, but was partially offset by increases in sales to Brazil and Pfizer.
• Revenue from license and R&D services decreased by 99% in the second quarter of 2024 compared to the same period in 2023, due to the absence of a milestone payment received in the prior year.
• Cost of goods sold increased by 56% in the second quarter of 2024 compared to the same period in 2023, primarily due to increased sales to Pfizer and Brazil.
• Research and development expenses decreased by 33% in the second quarter of 2024 compared to the same period in 2023, due to the completion of the Fabry clinical program.
• The company had $45 million in cash and cash equivalents and short-term bank deposits as of June 30, 2024.
• The company believes its current cash resources are sufficient to meet its capital needs for at least the next 12 months, including the redemption of the 2024 Notes.

Sentiment

Score: 4

Explanation: The document presents mixed results with a net loss and decreased revenues, but also highlights positive developments such as increased sales in some areas and reduced R&D expenses. The need for potential future capital raises and the ongoing conflict in Israel add to the uncertainty.

Positives

• Sales to Brazil and Pfizer increased in the second quarter of 2024 compared to the same period in 2023.
• Research and development expenses decreased due to the completion of the Fabry clinical program.
• The company believes its current cash resources are sufficient to meet its capital needs for at least the next 12 months.
• The company is in compliance with all financial covenants related to its 2024 Notes.
• The company collected approximately $4.6 million from sales to Pfizer and $2.3 million from sales to Brazil subsequent to the end of the quarter.

Negatives

• The company reported a net loss for both the three and six months ended June 30, 2024.
• Revenue from selling goods decreased by 12% in the second quarter of 2024 compared to the same period in 2023.
• Revenue from license and R&D services decreased significantly due to the absence of a milestone payment.
• Cost of goods sold increased by 56% in the second quarter of 2024 compared to the same period in 2023.

Risks

• The company's operations may be adversely affected by the ongoing conflict in Israel.
• The company may need to raise additional capital to fund future research and development activities.
• The company's ability to raise capital may be affected by the volatility of its stock price.
• The company is dependent on the performance of its collaborators, distributors, and partners.
• The company faces risks related to the regulatory approval and commercial success of its product candidates.

Future Outlook

The company expects to continue to incur significant expenditures in the near future due to research and development efforts with respect to product candidates and believes its current cash resources are sufficient to meet its capital needs for at least the next 12 months, including the redemption of the 2024 Notes.

Management Comments

• The company is committed to leveraging its track record of success as it progresses with the development of treatments for rare and orphan diseases.
• The company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases.
• The company intends to use its ProCellEx platform and PEGylization capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities.

Industry Context

The report highlights the competitive landscape in the rare disease market, mentioning competitors for both Gaucher and Fabry disease treatments. The company is focusing on developing new therapies for unmet needs, including renal diseases, which aligns with the industry trend of targeting rare and orphan diseases.

Comparison to Industry Standards

• The global market for Gaucher disease was $1.6 billion in 2023 and is forecasted to be approximately $1.6 billion in 2024, with a forecasted CAGR of approximately -0.57% from 2023-2030. Competitors include Sanofi's Cerezyme and Shire's Vpriv.
• The global market for Fabry disease is forecasted to be approximately $2.1 billion in 2024 and is forecasted to grow at a CAGR of 7.3% from 2023-2030, reaching approximately $3.2 billion in annual sales in 2023. Competitors include agalsidase beta, Sanofi's Fabrazyme, agalsidase alfa, Shire's Replagal, and Amicus Therapeutics' Galafold.
• The company's Elfabrio has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, and Israel, which positions it as a competitor in the Fabry disease market.
• The company's PRX-115 is being developed for uncontrolled gout, a market where Krystexxa (pegloticase) is a competitor, though it has a black box warning for anaphylaxis and other major side-effects.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may be concerned about the net loss and decreased revenues, but may be encouraged by the company's focus on new product development and its cash position.
• Employees may be affected by the company's financial performance and any potential changes in operations.
• Customers may be impacted by the company's ability to supply its products, particularly in light of the ongoing conflict in Israel.
• Suppliers may be affected by the company's financial performance and any potential changes in operations.
• Creditors may be concerned about the company's ability to repay its debts, particularly the 2024 Notes.

Next Steps

• The company will continue to develop its product candidates, including PRX-115 for uncontrolled gout and PRX-119 for NETs-related diseases.
• The company will continue to work with Chiesi on the commercialization of Elfabrio.
• The company expects to satisfy the outstanding principal and interest accrued under the 2024 Notes with a cash payment prior to the September 1, 2024 maturity date.
• The company will continue to monitor the impact of the ongoing conflict in Israel on its operations.

Key Dates

Keywords

Protalix BioTherapeutics, financial results, second quarter 2024, Elfabrio, Elelyso, Fabry disease, Gaucher disease, research and development, biopharmaceutical, recombinant proteins